Clinical trials: Chest--Diseases
Lung Cancer
Auris Robotic Endoscopy System for Bronchoscopy
In this study, the performance related to the use of the novel Robotic Endoscopy Platform during bronchoscopic procedures will be evaluated.
- Trial name
- NCT03497026
- Testing
- Robotic Bronchoscopy Platform
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Auris Health, Inc.
Non-small Cell Lung Cancer
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4 cycles of platinum based therapy.
- Trial name
- NCT01137968
- Testing
- imetelstat, Bevacizumab
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 116 people
- Sponsor
- Geron Corporation
Colorectal Cancer Metastatic, Triple Negative Breast Cancer
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and…
- Conditions
- Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03775850
- Testing
- EDP1503, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Evelo Biosciences, Inc.
Aorta, Thoracic Pathologies, Aortic Aneurysm, Thoracic
RE-GENERATION: The Safety and Performance of the Relay Pro and Relay NBS Pro Stent-graft Devices in the European Union (EU)
The objective of the study is to evaluate the safety and performance of Relay Pro and Relay NBS Pro devices in humans having thoracic aortic pathologies. Clinical results will be used to apply for the CE certification.
- Conditions
- Aorta, Thoracic Pathologies, Aortic Aneurysm, Thoracic, Aortic Aneurysm
- Trial name
- RE-GENERATION (NCT03207568)
- Testing
- Thoracic Endovascular Aortic Repair (TEVAR)
- Volunteers
- 30 people
- Sponsor
- Bolton Medical
Non Small Cell Lung Cancer
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer.
- Trial name
- NCT00890825
- Testing
- AZD6244, docetaxel
- Where
- 63 sites in United States, Belgium and 10 more
- Volunteers
- 88 people
- Sponsor
- AstraZeneca
Thoracic Aortic Aneurysm
STARZ-TX2 Clinical Study: Study of Thoracic Aortic Aneurysm Repair With the Zenith TX2 Endovascular Graft
The STARZ-TX2 trial (Study of Thoracic Aortic Aneurysm Repair with the Zenith TX2(R) TAA [Thoracic Aortic Aneurysm] Endovascular Graft) is a clinical trial approved by the United States Food and Drug Administration (FDA) to study…
- Trial name
- STARZ-TX2 (NCT00111176)
- Testing
- Endovascular repair, Surgical
- Where
- 41 sites in United States, Canada and 1 more
- Volunteers
- 260 people
- Sponsor
- Cook Group Incorporated
Non Small Cell Lung Cancer, Pancreatic Cancer
Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
The aim of the study is to assess the feasibility of genomic and epigenetic analysis of rectal mucus to detect non-colorectal cancers of the aero- digestive tract using samples collected by the OriCol™ Sampling Device.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- ORI-EGI-03 (NCT05102110)
- Testing
- Oricol Test
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- Origin Sciences
Non-Small Cell Lung Cancer, Lung Cancer
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation…
- Conditions
- Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
- Trial name
- NCT06685718
- Testing
- BG-60366
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 33 people
- Sponsor
- BeOne Medicines
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Neoplasm Metastasis
Study of Cryoablation for Metastatic Lung Tumors
The purpose of this study is to evaluate the safety and efficacy of cryoablation therapy used to treat tumors in participants with pulmonary metastatic disease.
- Trial name
- SOLSTICE (NCT01957787)
- Testing
- Cryoablation
- Where
- 10 sites in United States, France
- Volunteers
- 131 people
- Sponsor
- Boston Scientific Corporation
Non-small Cell Lung Cancer
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
To assess the efficacy and safety of Aumolertinib plus chemotherapy versus Aumolertinib alone as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor…
- Trial name
- NCT04923906
- Testing
- Aumolertinib
- Where
- China
- Volunteers
- 624 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Small Cell Lung Cancer
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment…
- Trial name
- NCT06064500
- Testing
- Tarlatamab
- Where
- 23 sites in United States, Brazil and 2 more
- Sponsor
- Amgen
Lung Cancer, Pulmonary Neoplasm
Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management.
- Trial name
- BioMolCTC (NCT06546007)
- Testing
- CTC-DNA
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Rarecells Diagnostics SAS
Non Small Cell Lung Cancer
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC…
- Trial name
- ATALANTE-1 (NCT02654587)
- Testing
- OSE2101, Docetaxel, Pemetrexed
- Where
- 78 sites in United States, Czechia and 8 more
- Volunteers
- 219 people
- Sponsor
- OSE Immunotherapeutics
Non Small Cell Lung Cancer
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
In Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients…
- Trial name
- NCT05742607
- Testing
- IPH5201 + durvalumab + standard chemotherapy
- Where
- 30 sites in United States, France and 3 more
- Volunteers
- 70 people
- Sponsor
- Innate Pharma
Lung Cancer, Non-small-cell Lung Carcinoma
A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
This is a Phase IIIb, multicenter, open-label trial of daily oral Tarceva in patients with advanced (inoperable Stage IIIb or IV) NSCLC who have progressed following standard chemotherapy treatment.
- Trial name
- NCT00091663
- Testing
- Tarceva (erlotinib HCl)
- Where
- 92 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Genentech, Inc.
Small Cell Lung Carcinoma (SCLC)
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that had previously received platinum-based chemotherapy and are eligible to receive a single agent…
- Trial name
- NCT05990738
- Testing
- BI 764532, Topotecan, Single agent chemotherapy
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 69 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Cancer, Advanced Solid Malignant Tumor
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be…
- Trial name
- SCLC (NCT05271292)
- Testing
- Chiauranib
- Where
- 11 sites in United States
- Volunteers
- 36 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
This is a Phase I, first-in-human, open-label study of CRPA1A2, a bispecific T-cell engager, in participants with HLA-A*02:01-positive and MAGE-A1-positive advanced solid tumors.
- Conditions
- Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07583316
- Testing
- CRPA1A2
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Adolescent Idiopathic Scoliosis
MESA Rail™ AIS Study - Preservation of Curve Correction
To evaluate the restoration and maintenance of thoracic kyphosis and coronal curve correction demonstrated through the surgical implantation of the K2M MESA Rail™ Deformity System as compared to literature reported outcomes for…
- Trial name
- NCT02062606
- Testing
- MESA Rail™ Deformity System
- Volunteers
- 188 people
- Sponsor
- K2M, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.